Denosumab for Treatment of Hypercalcemia of Malignancy

CONTEXT: Hypercalcemia of malignancy (HCM) in patients with advanced cancer is often caused by excessive osteoclast-mediated bone resorption. Patients may not respond to or may relapse after iv bisphosphonate therapy. OBJECTIVE: We investigated whether denosumab, a potent inhibitor of osteoclast-med...

Full description

Saved in:
Bibliographic Details
Main Authors: Hu, Mimi I., Glezerman, Ilya G., Leboulleux, Sophie, Insogna, Karl, Gucalp, Rasim, Misiorowski, Waldemar, Yu, Bennett, Zorsky, Paul, Tosi, Diego, Bessudo, Alberto, Jaccard, Arnaud, Tonini, Giuseppe, Ying, Wendy, Braun, Ada, Jain, Rajul K.
Format: Artigo
Language:Inglês
Published: Endocrine Society 2014
Subjects:
Endocrine Care
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4154084/
https://ncbi.nlm.nih.gov/pubmed/24915117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2014-1001
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items